Search hospitals > California > Santa Monica
UCLA Hematology Oncology - Santa Monica
Claim this profileSanta Monica, California 90404
Global Leader in Breast Cancer
Global Leader in Non-Small Cell Lung Cancer
Conducts research for Cancer
Conducts research for Solid Tumors
Conducts research for Tumors
91 reported clinical trials
7 medical researchers
Summary
UCLA Hematology Oncology - Santa Monica is a medical facility located in Santa Monica, California. This center is recognized for care of Breast Cancer, Non-Small Cell Lung Cancer, Cancer, Solid Tumors, Tumors and other specialties. UCLA Hematology Oncology - Santa Monica is involved with conducting 91 clinical trials across 81 conditions. There are 7 research doctors associated with this hospital, such as Zev A. Wainberg, Sara Hurvitz, MD, Jonathan W. Goldman, and Saeed Sadeghi.Area of expertise
1Breast Cancer
Global LeaderStage IV
HER2 negative
ER positive
2Non-Small Cell Lung Cancer
Global LeaderStage IV
Stage III
EGFR
Top PIs
Zev A. WainbergUCLA2 years of reported clinical research
Expert in Solid Tumors
Studies Pancreatic Cancer
30 reported clinical trials
62 drugs studied
Sara Hurvitz, MDUniversity of California, Los Angeles2 years of reported clinical research
Expert in Breast Cancer
Studies Tumors
17 reported clinical trials
24 drugs studied
Jonathan W. GoldmanUCLA / Jonsson Comprehensive Cancer Center5 years of reported clinical research
Studies Non-Small Cell Lung Cancer
Studies Lung Cancer
12 reported clinical trials
19 drugs studied
Saeed SadeghiUCLA Medical Center10 years of reported clinical research
Studies Bile Duct Cancer
Studies FGFR2 Mutation
6 reported clinical trials
8 drugs studied
Clinical Trials running at UCLA Hematology Oncology - Santa Monica
Breast Cancer
Non-Small Cell Lung Cancer
Pancreatic Cancer
Solid Tumors
Cancer
Colorectal Cancer
Tumors
Lung Cancer
Prostate Cancer
Lymphoma
Giredestrant + Hormone Therapy
for Early-Stage Breast Cancer
This study is evaluating whether a drug called giredestrant can improve the survival of women with early breast cancer.
Recruiting2 awards Phase 311 criteria
CoREST Inhibitor + Anti-PD-1 Therapy
for Solid Cancers
The goal of this interventional clinical trial is to learn about TNG260, a CoREST inhibitor, in combination with pembrolizumab in patients with advanced solid tumors with a known STK11 mutation. The main question[s] it aims to answer are: the recommended dose for Phase 2 to evaluate the safety and tolerability of the combination therapy to determine the pharmacokinetics of TNG260 to evaluate the initial antineoplastic activity Participants will receive study treatment until they experience an undesirable side effect, their disease progresses or until they withdraw consent.
Recruiting1 award Phase 1 & 2
Tucatinib + Trastuzumab + Pertuzumab
for Breast Cancer
This study is being done to see if tucatinib works better than placebo when given with other drugs to treat participants with HER2-positive breast cancer. A placebo is a pill that looks the same as tucatinib but has no medicine in it. This study will also test what side effects happen when participants take this combination of drugs. A side effect is anything a drug does to the body besides treating your disease. Participants will have cancer that has spread in the body near where it started (locally advanced) and cannot be removed (unresectable) or has spread through the body (metastatic). In this study, all participants will get either tucatinib or placebo. Participants will be assigned randomly to a group. This is a blinded study, so patients and their doctors will not know which group a participant is in. All participants will also get trastuzumab and pertuzumab. These are 2 drugs used to treat this type of cancer.
Recruiting1 award Phase 311 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at UCLA Hematology Oncology - Santa Monica?
UCLA Hematology Oncology - Santa Monica is a medical facility located in Santa Monica, California. This center is recognized for care of Breast Cancer, Non-Small Cell Lung Cancer, Cancer, Solid Tumors, Tumors and other specialties. UCLA Hematology Oncology - Santa Monica is involved with conducting 91 clinical trials across 81 conditions. There are 7 research doctors associated with this hospital, such as Zev A. Wainberg, Sara Hurvitz, MD, Jonathan W. Goldman, and Saeed Sadeghi.